Which has stronger valuation & earnings, ANTX or GLAS?

Glass House Brands has higher revenue and earnings than Anthem. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A Glass House Brands $176.02M 4.40 N/A N/A N/A

Is ANTX or GLAS more profitable?

Glass House Brands' return on equity of 0.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% Glass House Brands N/A N/A N/A

Does the media favor ANTX or GLAS?

In the previous week, Anthem had 1 more articles in the media than Glass House Brands. MarketBeat recorded 2 mentions for Anthem and 1 mentions for Glass House Brands. Anthem's average media sentiment score of 1.81 beat Glass House Brands' score of 0.59 indicating that Anthem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Glass House Brands 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ANTX or SGP?

Anthem is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A Spyglass Pharma N/A N/A N/A -$6.41 N/A

Is ANTX or SGP more profitable?

Spyglass Pharma's return on equity of 0.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% Spyglass Pharma N/A N/A N/A

Does the media prefer ANTX or SGP?

In the previous week, Spyglass Pharma had 1 more articles in the media than Anthem. MarketBeat recorded 3 mentions for Spyglass Pharma and 2 mentions for Anthem. Anthem's average media sentiment score of 1.81 beat Spyglass Pharma's score of 0.00 indicating that Anthem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ANTX or PHAT?

In the previous week, Phathom Pharmaceuticals had 13 more articles in the media than Anthem. MarketBeat recorded 15 mentions for Phathom Pharmaceuticals and 2 mentions for Anthem. Anthem's average media sentiment score of 1.81 beat Phathom Pharmaceuticals' score of -0.07 indicating that Anthem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Phathom Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, ANTX or OCS?

Anthem has higher earnings, but lower revenue than Oculis. Oculis is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A Oculis $1.45M 490.07 -$119.44M -$2.13 N/A

Is ANTX or OCS more profitable?

Anthem has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Anthem's return on equity of -52.35% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% Oculis -8,460.67% -56.78% -45.62%

Does the media prefer ANTX or OCS?

In the previous week, Oculis had 5 more articles in the media than Anthem. MarketBeat recorded 7 mentions for Oculis and 2 mentions for Anthem. Anthem's average media sentiment score of 1.81 beat Oculis' score of 0.78 indicating that Anthem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oculis 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ANTX or ACHV?

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A Achieve Life Sciences N/A N/A -$54.65M -$1.12 N/A

Is ANTX or ACHV more profitable?

Anthem's return on equity of -52.35% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% Achieve Life Sciences N/A -193.49% -111.88%

Does the media prefer ANTX or ACHV?

In the previous week, Achieve Life Sciences had 1 more articles in the media than Anthem. MarketBeat recorded 3 mentions for Achieve Life Sciences and 2 mentions for Anthem. Anthem's average media sentiment score of 1.81 beat Achieve Life Sciences' score of 0.27 indicating that Anthem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Achieve Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Anthem (ANTX) Competitors

$6.06 +0.23 (+3.85%)

As of 11:29 AM Eastern

Compare

ANTX vs. GLAS, SGP, PHAT, OCS, and ACHV

Should you buy Anthem stock or one of its competitors? MarketBeat compares Anthem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anthem include Glass House Brands (GLAS), Spyglass Pharma (SGP), Phathom Pharmaceuticals (PHAT), Oculis (OCS), and Achieve Life Sciences (ACHV). These companies are all part of the "pharmaceuticals" industry.

How does Anthem compare to Glass House Brands?

Anthem (NASDAQ:ANTX) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Glass House Brands' return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Glass House Brands	N/A	N/A	N/A

In the previous week, Anthem had 1 more articles in the media than Glass House Brands. MarketBeat recorded 2 mentions for Anthem and 1 mentions for Glass House Brands. Anthem's average media sentiment score of 1.81 beat Glass House Brands' score of 0.59 indicating that Anthem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Glass House Brands	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anthem currently has a consensus target price of $9.00, suggesting a potential upside of 48.39%. Glass House Brands has a consensus target price of $17.00, suggesting a potential upside of 76.07%. Given Glass House Brands' stronger consensus rating and higher possible upside, analysts clearly believe Glass House Brands is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Glass House Brands has higher revenue and earnings than Anthem.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Glass House Brands	$176.02M	4.40	N/A	N/A	N/A

90.5% of Anthem shares are held by institutional investors. 22.6% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Glass House Brands beats Anthem on 6 of the 11 factors compared between the two stocks.

How does Anthem compare to Spyglass Pharma?

Anthem (NASDAQ:ANTX) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Anthem currently has a consensus target price of $9.00, indicating a potential upside of 48.39%. Spyglass Pharma has a consensus target price of $45.00, indicating a potential upside of 83.31%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

90.5% of Anthem shares are held by institutional investors. 22.6% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anthem is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

Spyglass Pharma's return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Spyglass Pharma	N/A	N/A	N/A

In the previous week, Spyglass Pharma had 1 more articles in the media than Anthem. MarketBeat recorded 3 mentions for Spyglass Pharma and 2 mentions for Anthem. Anthem's average media sentiment score of 1.81 beat Spyglass Pharma's score of 0.00 indicating that Anthem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spyglass Pharma beats Anthem on 7 of the 11 factors compared between the two stocks.

How does Anthem compare to Phathom Pharmaceuticals?

Anthem (NASDAQ:ANTX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Anthem has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Anthem has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Phathom Pharmaceuticals	$239.66M	2.82	-$221.25M	-$1.28	N/A

90.5% of Anthem shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 22.6% of Anthem shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Anthem presently has a consensus target price of $9.00, indicating a potential upside of 48.39%. Phathom Pharmaceuticals has a consensus target price of $23.43, indicating a potential upside of 180.41%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Anthem has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

In the previous week, Phathom Pharmaceuticals had 13 more articles in the media than Anthem. MarketBeat recorded 15 mentions for Phathom Pharmaceuticals and 2 mentions for Anthem. Anthem's average media sentiment score of 1.81 beat Phathom Pharmaceuticals' score of -0.07 indicating that Anthem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Phathom Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Phathom Pharmaceuticals beats Anthem on 10 of the 16 factors compared between the two stocks.

How does Anthem compare to Oculis?

Anthem (NASDAQ:ANTX) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Anthem has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, Oculis has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Anthem currently has a consensus target price of $9.00, indicating a potential upside of 48.39%. Oculis has a consensus target price of $38.33, indicating a potential upside of 212.77%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

90.5% of Anthem shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 22.6% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Oculis had 5 more articles in the media than Anthem. MarketBeat recorded 7 mentions for Oculis and 2 mentions for Anthem. Anthem's average media sentiment score of 1.81 beat Oculis' score of 0.78 indicating that Anthem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oculis	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anthem has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Anthem's return on equity of -52.35% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Oculis	-8,460.67%	-56.78%	-45.62%

Anthem has higher earnings, but lower revenue than Oculis. Oculis is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Oculis	$1.45M	490.07	-$119.44M	-$2.13	N/A

Summary

Anthem beats Oculis on 8 of the 15 factors compared between the two stocks.

How does Anthem compare to Achieve Life Sciences?

Anthem (NASDAQ:ANTX) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

In the previous week, Achieve Life Sciences had 1 more articles in the media than Anthem. MarketBeat recorded 3 mentions for Achieve Life Sciences and 2 mentions for Anthem. Anthem's average media sentiment score of 1.81 beat Achieve Life Sciences' score of 0.27 indicating that Anthem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Achieve Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.5% of Anthem shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 22.6% of Anthem shares are held by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Anthem's return on equity of -52.35% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Achieve Life Sciences	N/A	-193.49%	-111.88%

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 48.39%. Achieve Life Sciences has a consensus price target of $16.00, suggesting a potential upside of 141.69%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Achieve Life Sciences is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Anthem has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, meaning that its share price is 124% more volatile than the broader market.

Summary

Anthem beats Achieve Life Sciences on 8 of the 14 factors compared between the two stocks.

Get Anthem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANTX vs. The Competition

Export

Metric	Anthem	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$219.16M	$11.76B	$6.91B	$12.89B
Dividend Yield	N/A	2.73%	2.60%	9.78%
P/E Ratio	-5.53	791.45	281.39	25.53
Price / Sales	N/A	745.50	573.11	80.50
Price / Cash	N/A	72.42	71.79	50.79
Price / Book	3.13	10.77	12.91	6.10
Net Income	-$35.17M	$2.82B	$3.49B	$348.34M
7 Day Performance	13.79%	2.74%	2.63%	3.32%
1 Month Performance	37.53%	-1.51%	-2.72%	-2.82%
1 Year Performance	464.19%	195.92%	75.99%	21.31%

Anthem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANTX Anthem	2.807 of 5 stars	$6.07 +3.9%	$9.00 +48.4%	+445.8%	$219.16M	N/A	N/A	N/A	Positive News
GLAS Glass House Brands	N/A	$9.66 -2.4%	$17.00 +76.0%	N/A	$774.63M	$176.02M	N/A	N/A	Gap Up
SGP Spyglass Pharma	2.1354 of 5 stars	$21.99 -3.2%	$45.00 +104.7%	N/A	$734.56M	N/A	N/A	65	Lockup Expiration
PHAT Phathom Pharmaceuticals	2.7298 of 5 stars	$8.95 -0.9%	$23.43 +161.8%	-1.8%	$713.82M	$204.89M	N/A	110
OCS Oculis	3.4407 of 5 stars	$11.15 -0.6%	$38.33 +244.0%	-32.3%	$646.30M	$1.45M	N/A	2	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANTX) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anthem (ANTX) Competitors

ANTX vs. GLAS, SGP, PHAT, OCS, and ACHV

How does Anthem compare to Glass House Brands?

Summary

How does Anthem compare to Spyglass Pharma?

Summary

How does Anthem compare to Phathom Pharmaceuticals?

Summary

How does Anthem compare to Oculis?

Summary

How does Anthem compare to Achieve Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anthem (ANTX) Competitors

ANTX vs. GLAS, SGP, PHAT, OCS, and ACHV

How does Anthem compare to Glass House Brands?

Is ANTX or GLAS more profitable?

Does the media favor ANTX or GLAS?

Do analysts rate ANTX or GLAS?

Which has stronger valuation & earnings, ANTX or GLAS?

Do institutionals and insiders believe in ANTX or GLAS?

Summary

How does Anthem compare to Spyglass Pharma?

Do analysts recommend ANTX or SGP?

Do insiders and institutionals have more ownership in ANTX or SGP?

Which has better valuation & earnings, ANTX or SGP?

Is ANTX or SGP more profitable?

Does the media prefer ANTX or SGP?

Summary

How does Anthem compare to Phathom Pharmaceuticals?

Which has more volatility & risk, ANTX or PHAT?

Which has higher earnings & valuation, ANTX or PHAT?

Do institutionals and insiders believe in ANTX or PHAT?

Do analysts prefer ANTX or PHAT?

Is ANTX or PHAT more profitable?

Does the media refer more to ANTX or PHAT?

Summary

How does Anthem compare to Oculis?

Which has more risk & volatility, ANTX or OCS?

Do analysts rate ANTX or OCS?

Do insiders & institutionals believe in ANTX or OCS?

Does the media prefer ANTX or OCS?

Is ANTX or OCS more profitable?

Which has stronger valuation and earnings, ANTX or OCS?

Summary

How does Anthem compare to Achieve Life Sciences?

Does the media prefer ANTX or ACHV?

Do institutionals and insiders hold more shares of ANTX or ACHV?

Is ANTX or ACHV more profitable?

Which has higher valuation & earnings, ANTX or ACHV?

Do analysts prefer ANTX or ACHV?

Which has more risk and volatility, ANTX or ACHV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools